Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aspirin/atenolol/hydrochlorothiazide/ramipril/simvastatin - Cadila Pharmaceuticals

Drug Profile

Aspirin/atenolol/hydrochlorothiazide/ramipril/simvastatin - Cadila Pharmaceuticals

Alternative Names: Polycap; Polypill - Cadila Pharmaceuticals; Quintapill

Latest Information Update: 27 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cadila Pharmaceuticals
  • Class Antihyperlipidaemics; Antihypertensives; Antiplatelets; Benzothiadiazines; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Naphthalenes; Propanolamines; Salicylates; Small molecules
  • Mechanism of Action ACE inhibitors; Beta 1 adrenergic receptor antagonists; Cyclooxygenase inhibitors; HMG-CoA reductase inhibitors; Platelet aggregation inhibitors; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Coronary disorders; Stroke

Most Recent Events

  • 30 Aug 2021 Cadila Pharnmaceuticals and Population Health Research Institute completes a Phase-III TIPS-3 trial in Cardiovascular disorders (Prevention) in Philippines, Tunisia, Colombia, Canada, Malaysia, Bangladesh, India and Tanzania (PO) (NCT01646437)
  • 04 Feb 2019 Chemical structure information added
  • 30 Jan 2014 Hydrochlorothiazide/atenolol/ramipril/simvastatin/aspirin - Cadila Pharmaceuticals is available for licensing in World as of 12 Apr 2009.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top